Calliditas Therapeutics AB (publ)
CLTEF · OTC
5/31/2025 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $563 | $4 | $4 | $6 |
| - Cash | $0 | $1 | $0 | $0 |
| + Debt | $0 | $1 | $0 | $0 |
| Enterprise Value | $563 | $4 | $4 | $5 |
| Revenue | $0 | $1 | $1 | $0 |
| % Growth | -100% | 50.3% | 250.1% | – |
| Gross Profit | -$0 | $1 | $0 | $0 |
| % Margin | -55.8% | 95% | 9.4% | 100% |
| EBITDA | -$2 | -$0 | -$0 | -$0 |
| % Margin | -9,435,477% | -32% | -51.4% | -215.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -558.6% | -38.6% | -4.9% | -24.1% |
| EPS Diluted | -0.058 | -8.69 | -7.78 | -9.84 |
| % Growth | 99.3% | -11.7% | 20.9% | – |
| Operating Cash Flow | -$1 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$1 | -$0 | -$0 | -$0 |